A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)

Sponsor

Institute of Cancer Research, United Kingdom (Other)

Overall Status

Completed

CT.gov ID

NCT02057913

Collaborator

St George's Healthcare NHS Trust (Other)

Enrollment

Locations

Arm

55.7

Actual Duration (Months)

2.4

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

VinCaP is a multicentre single-arm phase II trial. 22 patients will receive Vinflunine chemotherapy (Vinflunine 320mg/m2 given intravenously on day 1 of each cycle of 21 days, four cycles to be given prior to formal re-staging).

Condition or Disease	Intervention/Treatment	Phase
Locally-advanced or Metastatic Penile Neoplasms	Drug: Vinflunine	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

22 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis

Actual Study Start Date :

Mar 17, 2014

Actual Primary Completion Date :

Nov 6, 2018

Actual Study Completion Date :

Nov 6, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Vinflunine All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.	Drug: Vinflunine All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging. Other Names: Javlor

Arm

Intervention/Treatment

Experimental: Vinflunine

All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.

Drug: Vinflunine

Other Names:

Javlor

Outcome Measures

Primary Outcome Measures

Clinical Benefit [12 weeks]
To determine the clinical benefit (objective response & stable disease rate) and toxicity of vinflunine in patients with inoperable (locally advanced or metastatic) cancer of the penis and thus determine whether this drug warrants further research in this indication.

Secondary Outcome Measures

Objective Response Rate [12 weeks]
Proportion of patients having achieved partial or complete remission. The proportion of patients with objective response will be calculated and presented along its 95% confidence interval.
Toxicity [Baseline, 3, 6, 9, 12 weeks on treatment, and at follow-up, 3, 6, 9, 12, 18, 24 months (timed from end of last cycle of chemotherapy)]
Toxicity will be evaluated, using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4 scoring, after each cycle, at the end of treatment and at follow up visits. The proportion of patients experiencing grade 3 or 4 toxicities at these time points and until progression will be reported as well as the Serious Adverse Events (SAEs).
Progression-free survival [From registration to first documented disease progression or death from any cause, up to 24 months]
Progression-free survival will be defined as time from registration until the first of clinically or radiologically documented disease progression, or death from any cause death. Patients alive and progression-free at time of analysis will be censored at date last seen.
Overall Survival [Time from registration until death from any cause, up to 24 months]
Patients alive at time of analysis will be censored at date last seen. Patients lost to follow-up will be censored at date last seen.
Treatment Compliance [12 weeks]
Treatment Compliance will be defined as proportion of planned doses delivered. Reasons for non-delivery of planned doses (patient or clinician preference, toxicity and tolerability) will be collected.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Male, ≥18 years.
Measurable disease as determined by RECIST (Response Evaluation Criteria in Solid Tumors) criteria (version 1.1).
Patients who present with purely cutaneous measurable disease should fulfill RECIST Criteria (see Appendix 1). Lesions should be a minimum size of 10 mm and measured using calipers by clinical examination.
Histologically-proven squamous cell carcinoma of the penis.
Stage: M1, or; M0, any T, N3 (i.e. involvement of deep inguinal or pelvic lymph nodes) or; M0, any T, N2 (i.e. involvement of multiple or bilateral superficial lymph nodes) or; M0, T4 (tumour invades other adjacent structures) any N.

Notes:

Patients with M0 disease may be considered if, in the opinion of the specialist Multi Disciplinary Team (MDT), they are deemed unlikely to benefit from surgery with curative intent and unlikely to tolerate combination chemotherapy due to comorbidities and/or disease burden.
Patients who have received prior radiotherapy to non-target lesions may be included.
Pre-treatment blood counts, haematology and biochemistry values within the following acceptable limits: Absolute Neutrophil Count (ANC) ≥ 1,500/mm3, Platelets ≥100,000/mm3, glomerular filtration rate (GFR) ≥60ml/min. GFR to be assessed according to local practice (recommended technique of eGFR using the MDRD formula.
Liver function: Patients must have (with or without the presence of liver metastases):

A prothrombin time >70% normal value (NV) AND
Bilirubin <1.5xUpper Limit of Normal (ULN) AND
Transaminases <2.5xULN AND
GGT <5xULN

Performance Status Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2.
Written, informed consent.

Exclusion Criteria:

Pure verrucous carcinoma of the penis.
Squamous carcinoma of the urethra.
Patients who do not have measurable disease as determined by RECIST (version 1.1).
T1 N1 M0 disease.
T2 N1 M0 disease.
M0, T3, N1 (tumour invades urethra or prostate and single inguinal node involved).
Unfit for vinflunine chemotherapy (as assessed by the multidisciplinary team).
Previous chemotherapy or chemoradiotherapy.
Contraindication to chemotherapy.
Other malignancy (other than Squamous Cell Carcinoma or Basal Cell Carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last 5 years. All patients with a previous cancer diagnosis must be discussed the Chief Investigator prior to entry into the trial.
Patients who have received radiotherapy to target lesions and have no other lesions that can act as target lesions instead:

e.g. Patients with recurrent pelvic lymph nodes that are deemed irresectable and who have had prior radiotherapy to those lymph nodes:

are INELIGIBLE if the involved lymph nodes are the only site of disease.
are ELIGIBLE if they have other measurable sites of disease e.g. pulmonary metastases.

If uncertain, please discuss with the Chief Investigator.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Velindre NHS Trust	Whitchurch	Cardiff	United Kingdom	CF14 2TL
2	Royal Cornwall Hospitals NHS Trust	Truro	Cornwall	United Kingdom	TR1 3LJ
3	University College London Hospitals NHS Foundation Trust	London	Greater London	United Kingdom	NW1 2PG
4	The Christie NHS Foundation Trust	Manchester	Greater Manchester	United Kingdom	M20 4BX
5	St George's Healthcare NHS Trust	Tooting	London	United Kingdom	SW17 0QT
6	Clatterbridge Centre for Oncology NHS Foundation Trust	Wirral	Merseyside	United Kingdom	CH63 4JY
7	Beatson West of Scotland Cancer Centre	Glasgow		United Kingdom	G12 0YN
8	St James's University Hospital	Leeds		United Kingdom	LS79 7TF
9	Leicester Royal Infirmary	Leicester		United Kingdom	LE1 5WW